GleamWall
中文EN

ERNA Ernexa Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 748592 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY755.9%
TTM net income YoY-105.6%
TTM EPS YoY-1,100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin83.5%
Operating margin-2,693.1%
Net margin-7,652.7%
FCF margin-2,784.4%
EBITDA margin-2,648.8%

Returns

ROE-2,264.3%
ROA-163.7%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets67.7%
Debt / equity0.00x
Current ratio0.80x
Interest coverage2.09x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-105.5%
Payout ratio—
Capex / revenue63.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$1,000
Cost of revenue$0$0——$0$0—$0
Gross profit———————$1,000
R&D expense$1.87M$2.79M$1.92M$676,000$1.03M$1.14M$1.31M$1.16M
SG&A expense$1.12M$1.31M$1.63M$1.42M$958,000$1.36M$1.42M$1.54M
Operating income-$2.99M-$4.10M-$5.59M-$2.09M-$1.99M-$2.50M-$2.73M-$2.70M
Interest expense———-$122,000$0-$778,000$6,000-$10.10M
Pretax income-$2.94M-$4.01M-$5.55M-$1.56M-$1.23M-$3.14M-$8.19M-$5.75M
Income tax$0$0-$40,000-$62,000$6,000$3,000$8,000$11,000
Net income-$2.94M-$4.01M-$5.51M-$1.50M-$1.24M-$3.14M-$8.20M-$5.76M
EBITDA-$2.89M-$4.00M-$5.58M-$2.08M-$1.99M-$2.00M-$2.71M-$2.68M
EPS (basic)-1.89-3.40-6.95—-3.77-15.19-57.76—
EPS (diluted)-1.89-3.40-6.95—-3.77-15.19-57.76—
Weighted avg. shares (diluted)1.56M1.18M792,000—329,000207,000142,000—
Balance sheet
Cash & equivalents$5.58M$5.03M$9.18M$1.88M$3.05M$4.32M$1.92M$1.73M
Current assets$6.73M$5.89M$10.00M$3.13M$3.38M$4.79M$2.21M$2.35M
PP&E, net$73,000$82,000$88,000$94,000$92,000$50,000$67,000$85,000
Goodwill———$2.04M$2.04M$2.04M$2.04M$2.04M
Total assets$7.10M$6.32M$10.54M$5.83M$6.17M$7.58M$5.06M$5.27M
Current liabilities$2.61M$2.93M$3.46M$3.11M$2.14M$2.65M$10.44M$2.94M
Total liabilities$2.75M$3.12M$3.68M$3.43M$2.60M$3.14M$11.01M$3.57M
Shareholders' equity$4.35M$3.20M$6.86M$2.40M$3.57M$4.44M-$5.95M$1.70M
Shares outstanding1.65M1.17M1.17M314,0007.85M7.48M52.25M3.43M
Cash flow statement
Operating cash flow-$3.17M-$4.15M-$2.26M-$1.15M-$1.27M-$2.53M-$2.06M-$3.54M
Capital expenditure$0$3,000$2,000$15,000———$0
Free cash flow-$3.17M-$4.16M-$2.27M-$1.16M———-$3.54M
Investing cash flow$0-$3,000-$2,000-$15,000———$0
Financing cash flow$3.72M$6,000$9.56M$0$26,000$4.93M$2.25M$1.01M
Depreciation & amortization$100,000$100,000$8,000$13,000$0$500,000$18,000$19,000
Stock-based compensation$377,000$320,000$309,000$333,000$293,000$368,000$502,000$410,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.